Atrinsic (PTIX) Short Interest Ratio & Short Volume

Short interest is the volume of Atrinsic shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 10,900 shares of PTIX short. 1.46% of Atrinsic's shares are currently sold short. Learn More on Atrinsic's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.46% of Atrinsic's floating shares are currently sold short.

Atrinsic saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 10,900 shares, an increase of 10.1% from the previous total of 9,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Atrinsic currently has issued a total of 590,000 shares. Some of Atrinsic's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atrinsic currently has a public float of 749,000 shares.

1.46% of Atrinsic's shares are currently sold short. Here is how the short interest of companies compare to Atrinsic: Servotronics, Inc. (1.69%), Apollomics Inc. (3.64%), NKGen Biotech, Inc. (1.86%), Genprex (4.20%), Purple Biotech Ltd. Sponsored ADR (5.22%), Pasithea Therapeutics Corp. (1.20%), HCW Biologics Inc. (4.25%), VYNE Therapeutics Inc. (15.33%), Tharimmune, Inc. (0.29%), Briacell Therap (2.06%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling PTIX is an investing strategy that aims to generate trading profit from Atrinsic as its price is falling. PTIX shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Atrinsic occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTIX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTIX, twice per month. The most recent reporting period available is July, 31 2025.